Releasing the brakes: a case report of pulmonary arterial hypertension induced by immune checkpoint inhibitor therapy
Matthew Glick, C. Baxter, David López, Kashif Mufti, Stephen G. Sawada, Tim Lahm
Abstract
Immune checkpoint inhibitors successfully treat various malignancies by inducing an immune response to tumor cells. However, their use has been associated with a variety of autoimmune disorders, such as diabetes, hepatitis, and pneumonitis. Pulmonary arterial hypertension due to checkpoint inhibitor use has not yet been described. We present a novel case of pulmonary arterial hypertension associated with systemic lupus erythematosus and Sjogren's syndrome overlap that was induced by therapy with the checkpoint inhibitor durvalumab.
Topics & Concepts
MedicineDurvalumabPulmonary hypertensionImmune checkpointImmune systemNivolumabImmunologyImmunotherapyInternal medicinePulmonary Hypertension Research and TreatmentsPeptidase Inhibition and AnalysisCoagulation, Bradykinin, Polyphosphates, and Angioedema